MALVERN, Pa.--(BUSINESS WIRE)--July 7, 2005--The preliminary results of an ongoing study, “Clinical Experience Using A Novel Bio-Composite For Treating Vertebral Compression Fractures in Vertebroplasty and Kyphoplasty; Report On The First 40 Patients,” conducted by Orthovita, Inc., (NASDAQ NM:VITA) and involving patients with vertebral compression fractures will be presented in an abstract at the International Meeting on Advanced Spine Techniques in Banff, Canada. Hyun Bae, M.D., lead author of the study, will present the findings in a podium presentation at IMAST being held from July 7 through July 9, 2005 at the Fairmont Banff Springs Hotel. The purpose of the two pilot IDE studies, conducted in 20 patients each, was to obtain preliminary information for assessing the feasibility and clinical outcome in using CORTOSS(R), Orthovita’s product to treat osteoporotic vertebral compression fractures. Patients in the study were treated minimally invasively with CORTOSS using either the vertebroplasty technique, where CORTOSS is injected directly into the fracture area, or the kyphoplasty technique, where a balloon is first inserted into the fracture area and inflated to create a void prior to injection of CORTOSS into the fracture area.
